Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Crystal Denlinger, MD, regarding cell free DNA tests and their influence on the treatment of CRC patients

Crystal Denlinger, MD, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, regarding cell free DNA tests and how they can influence decision making when treating colorectal cancer patients

Tags: ASCO GI Conference CoverageColorectal

Published: 31 January 2020

Recent Videos: Colorectal

video

Tilak Sundaresan, MD, regarding the results of the TAPUR study and its importance to physicians

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, regarding the results of the TAPUR study presented at ASCO ...

video

Tilak Sundaresan, MD, determines whether to automatically test for the BRAF mutation in patients

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, determines whether to automatically test for the BRAF mutation in ...

video

Tilak Sundaresan, MD, shares how "sided-ness" affects the use of EGFR inhibitors in CRC treatment

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, shares how the recent clinical studies concerning "sided-ness" affects the ...

video

Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, provided perspective on the combination of regorafenib and checkpoint inhibitors ...

video

Tilak Sundaresan, MD, elaborates on the influence of cell free DNA when managing CRC patients

Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, elaborates on the influence of cell free DNA when making ...

video

Crystal Denlinger, MD, offers opinion on checkpoint inhibitors being used in anal cancer management

Dr. Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, offers opinion regarding checkpoint inhibitors being used in ...

video

Crystal Denlinger, MD, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI

Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, discusses quality of life analysis in the IMBRAVE ...

video

Crystal Denlinger, MD, regarding cell free DNA tests and their influence on the treatment of CRC patients

Crystal Denlinger, MD, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, regarding cell free DNA tests and how ...

video

Crystal Denlinger, MD, comments on the use of fitness trackers in regards to management of CRC

Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, comments on the use of fitness trackers to ...

video

David H Ilson, MD, elaborates on updated data from the BEACON study presented at ASCO GI 2020

Dr. Ilson, Memorial Sloan Kettering Cancer Center, elaborates on updated data regarding the BEACON study presented this year at ...

Related Videos

video-image

Tilak Sundaresan, MD, regarding the results of the TAPUR study and its importance to physicians

video-image

Tilak Sundaresan, MD, determines whether to automatically test for the BRAF mutation in patients

video-image

Tilak Sundaresan, MD, shares how "sided-ness" affects the use of EGFR inhibitors in CRC treatment

video-image

Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC

video-image

Tilak Sundaresan, MD, elaborates on the influence of cell free DNA when managing CRC patients

video-image

Crystal Denlinger, MD, offers opinion on checkpoint inhibitors being used in anal cancer management

video-image

Crystal Denlinger, MD, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI

video-image

Crystal Denlinger, MD, comments on the use of fitness trackers in regards to management of CRC

video-image

David H Ilson, MD, elaborates on updated data from the BEACON study presented at ASCO GI 2020

video-image

Zev Wainberg, MD, on the role of pembrolizumab for MSI high CRC patients and its use in therapy

video-image

Manish Shah, MD, describes BRAF testing tactics and how it affects treatment of CRC patients

video-image

Ryan Corcoran, MD, on the current use of MRD as a valid test for determining GI cancer treatment

video-image

Ryan Corcoran, MD, explains the need for the MRD test in CRC and whether its ready for prime time

video-image

Ryan Corcoran, explains cell free DNA and ways to test for it

video-image

Richard Kim, MD, on results of phase 1 study regarding locally advanced rectal adenocarcioma

video-image

Richard Kim, MD, explains how "sided-ness" affects usage of EGFR inhibitors in the treatment of CRC

video-image

Benjamin Weinberg, comments on the use of intratumoral microbiome assessment vs GI tract assessment

video-image

Benjamin Weinberg, MD, on the microbiome and the development of colorectal malignancies

video-image

Benjamin Weinberg, MD, on demographic results associated with the microbiome and CRC

video-image

Crystal Denlinger, MD, explains differentiation of treatment of CRC patients based on age

video-image

Crystal Denlinger, MD, shares data regarding first line biliary tract cancer patients

video-image

David H Ilson, MD, shares perspective of the IPACS study regarding stage 4 CRC patients

video-image

Ryan Corcoran, MD, elaborates on promising clinical applications of cell free DNA

video-image

Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC

video-image

Stefan Kasper, MD, provides updates on the BEACON trial in BRAF-mutant CRC

video-image

Deborah Shrag, MD, MPH, on which biomarkers are important in the diagnosis & management of CRC

video-image

Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer

video-image

Stefan Kasper, MD, explains the dosing and administration schedule of cetuximab

video-image

Marwan Fakih, MD, considers implications from the AMG 510 trial

video-image

Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patients

video-image

Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in CRC and NSCLC

video-image

Marwan G. Fakih, MD, on combining regorafenib + checkpoint inhibition in advanced CRC

video-image

Marwan G. Fakih, MD, on why AMG 510 seems promising in colorectal and lung cancers

video-image

Marwan G. Fakih, MD, describes the role of KRAS inhibitors in colorectal cancer

video-image

Leonard Saltz, MD, offers opinion on the value of of liquid biopsy in colorectal cancer treatment

video-image

Leonard Saltz, MD, offers opinion on molecular profiling in the treatment of CRC

video-image

Leonard Saltz, MD, considers the complexities of managing metastatic colorectal cancer

video-image

Leonard Saltz, MD, on whether data presented at ASCO '19 will change the way we treat CRC

video-image

John Strickler, MD, on how next-generation sequencing fits into treatment of mCRC

video-image

Raymond Wadlow, MD, regarding BSC vs. combination checkpoint inhibitors in advanced CRC

video-image

Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer

video-image

Axel Grothey, MD, on the CCTG CO.26 trial in advanced refractory CRC presented at GI 2019

video-image

Axel Grothey, MD, on the use of regorafenib in the management of advanced CRC

video-image

Axel Grothey, MD, on patient selection & treatment algorithms in 2nd and 3rd line CRC

video-image

Alan Venook, MD, tells us whether ctDNA is a valid treatment response in CRC

video-image

Axel Grothey, MD, considers the role of circulating tumor DNA (ctDNA)

video-image

Alan Venook, MD, discusses next generation sequencing and mCRC treatment

video-image

Axel Grothey, MD, elaborates on next generation sequencing and mCRC

video-image

Philip Philip MD, PhD, FRCP, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer

video-image

Jeffrey A. Meyerhardt, MD, on genetic testing in newly diagnosed mCRC

video-image

Howard Hochster, MD, on how checkpoint inhibitors are impacting treatment algorithms in mCRC

video-image

Jeffrey A. Meyerhardt, MD, shares thoughts on checkpoint inhibitors in adjuvant CRC

video-image

Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisions

video-image

Jeffrey A. Meyerhardt, MD, on managing 2nd and 3rd line mCRC patients

video-image

Howard Hochster, MD, on the management of mCRC patients receiving regorafenib

video-image

Jeffrey A. Meyerhardt, MD, on whether regorafenib is becoming more tolerable for mCRC patients

video-image

Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patients

video-image

Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer

video-image

Howard Hochster, MD, regarding the role of genetic testing in mCRC

video-image

Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting

video-image

Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC

video-image

Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment

video-image

Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer

video-image

John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”

video-image

John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms

video-image

John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC

video-image

Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC

video-image

Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018

video-image

Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC

video-image

Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"

video-image

Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients

video-image

Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms

video-image

Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC

video-image

Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients

video-image

Steven J. Cohen, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Steven J. Cohen, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Steven J. Cohen, MD, provides insight into sequencing and efficacy outcomes in 2nd line mCRC

video-image

Steven J. Cohen, MD, describes how tumor sidedness impacts treatment decisions in mCRC

video-image

Steven J. Cohen, MD, regarding combination atezolizumab + cobimetinib in mCRC patients

video-image

Steven J. Cohen, MD, considers the improvement in duration of therapy examined in the ReDOS study

video-image

Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study

video-image

Philip Philip, MD, PhD, FRCP, discusses the impact of the Checkmate 142 study on mCRC

video-image

Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, on dose escalation of regorafenib as a result of the ReDOS study

video-image

Jeffrey Meyerhardt, MD, MPH, discusses the length of adjuvant therapy for colorectal cancer patients

video-image

Jeffrey Meyerhardt, MD, MPH, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC

video-image

Jeffrey Meyerhardt, MD, MPH, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment

video-image

Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients

video-image

Scott Kopetz, MD, PhD, FACP, considers the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients

video-image

Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients

video-image

Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC

video-image

Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms

video-image

Alan Venook, MD, on the impact of dose escalation of regorafenib in mCRC patients

video-image

Alan Venook, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients

video-image

Alan Venook, MD, explains how tumor sidedness affects therapeutic choice

video-image

Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients

video-image

Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy

video-image

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib

video-image

Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients

video-image

Howard Hochster, MD, discusses the optimal duration of FOLFOX therapy in stage III colon cancer

video-image

Howard Hochster, MD, on the impact of SWOG 1406 in treating BRAF mutation positive CRC patients

video-image

Richard Goldberg, MD, FASCO, regarding the optimal duration of therapy in stage III colon cancer

video-image

Richard Goldberg, MD, FASCO, defines “high-risk” and “low-risk” stage III colon cancer patients

video-image

Leonard Saltz, MD, reflects on intriguing CRC clinical data presented at ASCO 2017

video-image

Leonard Saltz, MD, offers opinion on the optimal duration of adjuvant chemotherapy in colon cancer

video-image

Philip Philip, MD, on what we’ve learned about the duration of therapy in the adjuvant CRC setting

video-image

John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach

video-image

John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision

video-image

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

video-image

Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient

video-image

Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

video-image

Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient

video-image

Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

video-image

Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients

video-image

Tanios Bekaii-Saab, MD, on developing effective immunotherapies in CRC patients

video-image

Tanios Bekaii-Saab, MD, on progress in developing immunotherapies in non MSI- High CRC patients

video-image

Bert O’Neill, MD, on making immunotherapy more effective in mCRC

video-image

Alan Venook, MD on whether CALGB/SWOG 80405 study provides guidance on therapeutic regimen

video-image

Tanios Bekaii-Saab, MD, on how clinicians factor economics into therapeutic decision making

video-image

Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumab

video-image

Howard Hochster, MD on the economic benefit seen in CALGB/SWOG 80405

video-image

Howard Hochster, MD talks progress in the development of effective non MSI-High immunotherapies

video-image

Tanios Bekaii-Saab, MD, on performance status when selecting mCRC, 3rd line treatment therapy

video-image

Tanios Bekaii-Saab, MD, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC

video-image

Tanios Bekali-Saab, MD, on utilizing regorafenib (Stivarga) and trifluridine (Lonserf)

video-image

Tanios Bekali-Saab, MD, comments on sequencing of immunotherapeutic agents in mCRC patients

video-image

Tanios Bekaii-Saab, MD on MSI-High as an mCRC response predictor to nivolumab (Opdivo)

video-image

Tanios Bekali-Saab, MD, tells us whether KRAS is a definitive biomarker in mCRC patients

video-image

Tanios Bekaii-Saab, MD on outcomes of CALGB/SWOG 80404 and potential impact

video-image

Tanios Bekaii-Saab, MD, comments on outcomes of CALGB/SWOG 80404 regarding primary site of tumor

video-image

Alan Venook, MD talks about treatment strategies based on site of primary tumor in CRC patients

video-image

Alan Venook, MD, explains the biological difference between left-sided and right-sided CRC tumors

video-image

Alan Venook, MD explains the outcome of phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD explains results from the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD discusses the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD explains how OS from primary site of tumor may impact treatment

video-image

Jeffrey A. Meyerhardt, MD on the reliability of MSI-High as a predictor of response in mCRC

video-image

Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients

video-image

Jeffrey A. Meyerhardt, MD explains integration of Stivarga and Lonserf in later lines of treatment

video-image

Jeffrey A. Meyerhardt, MD weighs in on the economic vs efficacy outcomes in CALGB/SWOG 80405

video-image

Jeffrey A. Meyerhardt, MD, explains matching mutations and markers to therapies in CRC patients

video-image

Philip Philip, MD on Stivarga (regorafenib) dosage in 2nd line treatment of mCRC

video-image

Philip Philip, MD explains how to integrate regorafenib and trifluridine for 2nd line mCRC treatment

video-image

Philip Philip, MD on the importance of ipilimumab prior to nivolumab in mCRC patients

video-image

Philip Philip, MD on the reliability of MSI-High as a predictor of response to Opdivo in mCRC

video-image

Philip Philip, MD discusses phase 3 CALGB/SWOG 80405 study outcomes

video-image

Philip Philip, MD on what is impressing him at ASCO 2016 in CRC

video-image

Jeffrey A. Meyerhardt, MD on PD-1 or PD-L1 treatment strategies for MSI-Stable mCRC patients

video-image

Bert O'Neil, MD discusses decision making based on toxicities factor for later lines of mCRC therapy

video-image

Howard Hochster, MD explains outcomes from the phase 3 CALGB/SWOG 80405 study

video-image

Howard Hochster, MD on mCRC treatment changes due to primary site of tumor impact.

video-image

Howard Hochster, MD talks about predictive response therapy based on site of tumor in mCRC

video-image

Howard Hochster, MD on performance status importance in selecting treatment algorithms

video-image

Richard Goldberg, MD, talks patient response with the combination of MEK and PD-1 inhibitors

video-image

Richard Goldberg, MD, discusses selecting the right therapeutic approach for CRC patients

video-image

Richard M. Goldberg, MD, FASCO on KRAS wild type or mutant in right or left-sided mCRC patients

video-image

Richard M. Goldberg, MD, FASCO on regimen preference in mCRC 1st line treatment

video-image

Richard M. Goldberg, MD, FASCO discusses outcomes of the phase 3 CALGB/SWOG 80405 study

video-image

Bert O'Neil, MD on integrating regorafenib and trifluridine into later lines of mCRC treatment

video-image

Bert O'Neil, MD and the combination of ipilimumab with nivolumab in mCRC patients

video-image

Bert O'Neil, MD on the importance of choosing mCRC treatment based on primary tumor site

video-image

Alan Venook, MD discusses development of immunotherapies for non MSI-High CRC patients

video-image

Alan Venook, MD, balancing economics with the efficacy outcomes seen in 80405

video-image

Alan Venook, MD relays the optimal dose for regorafenib (Stivarga) in the 2nd line treatment of mCRC

video-image

Alan Venook, MD on integrating regorafenib and trifluridine into the 2nd line treatment of mCRC

video-image

Alan Venook, MD on reliability of MSI-High predictor fpr response to nivolumab (Opdivo) in mCRC

video-image

Alan Venook, MD relates data presented in EPIC study relates to CALGB/SWOG 80405

video-image

Choosing which EGFR inhibitor to use in second line treatment of mCRC patients At ASCO GI 2016

video-image

RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016

video-image

Integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016

video-image

RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC

video-image

Biggest questions facing the treatment of colorectal cancer ASCO GI 2016

video-image

How has the last 10 years changed the way you treat metastatic colorectal cancer ASCO GI 2016

video-image

Immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016

video-image

Regorafenib experience and integrating TAS-102 for advanced CRC ASCO GI 2016

video-image

ERCC1 not a valid prognostic or predictive factor in advanced CRC ASCO GI 2016

video-image

STEAM trial may not change treatment paradigm for metastatic CRC ASCO 2016

video-image

RAS mutation in patients with metastatic colorectal cancer ASCO GI 2016

video-image

ASCO GI 2016 Optimal Dosage Using Regorafenib Colorectal Cancer

video-image

Immunotherapy Shows Promise in MSI-High Colorectal Cancer

video-image

Future of TAS-102 and regorafenib for patients with colorectal cancer

video-image

Tom Beer, MD, describes use of DNA repair markers when determining treatment of prostate cancer

video-image

David H Ilson, MD, on the JAVELIN 100 study and the need for quick responses and immunotherapy in GE

video-image

Zev Wainberg, MD, explains appropriate therapy following initial treatment for GI & GE tumors

video-image

Zev Wainberg, MD, shares the best way to combine checkpoint inhibitors in gastric and GE tumors

video-image

Zev Wainberg, MD, on the line of therapy for checkpoint inhibitors in gastric and GI cancers

video-image

Hani Babiker, MD, on tumor treatment field combinations in the management of GI malignancies

video-image

Hani Babiker, MD, defines tumor treatment fields as well as the mechanism of action

video-image

Ahmed Kaseb, MD, on the differentiation of levatinib vs cabozantinib for HCC treatment

video-image

Ahmed Kaseb, MD, explains the role of immunotherapy in neo-adjuvant treatment of resectable HCC

video-image

Ahmed Kaseb, MD, shares the role of checkpoint inhibitors when alone and combined with anti-CTLA4

video-image

Irvin Modlin, MD, explains the reason NETest is more effective than a biomarker test such as CGA

video-image

Irvin Modlin, MD, describes whether NETest replaces or supplements imaging

video-image

Irvin Modlin, MD, offers opinion of NETest and whether it is cost prohibitive

video-image

Irvin Modlin, MD, explains the specificity and sensitivity of the NETest

video-image

Irvin Modlin, MD, shares importance of NETest, requirement for testing, and where to send results

video-image

Nevena Damjanov, MD, shares personal opinion of treatment of patient with a high expression of AFP

video-image

Eileen O'Reilly, MD, shares outcomes of the POLO study and its importance to physicians

video-image

Eileen O'Reilly, MD, describes how physicians should test for BRCA in pancreatic cancer patients

video-image

Sam Klempner, MD, describes the role of Cyramza in the treatment of GR junction cancers

video-image

Sam Klempner, MD, considers promising approaches to therapy in development for upper GI malignancies

video-image

Manish Shah, MD, discusses avelumab's effectiveness based on results from the JAVELIN 100 study

video-image

Manish Shah, MD, explains whether levatinib can be combined with I-O to treat and manage GI cancer

video-image

Irvin Modlin, MD, on when to use NETest clinically and situations it has clinical utility

video-image

Daniel Catenacci, MD, on the role of margetuximab to improve treatment outcomes of GI cancers

video-image

Daniel Catenacci, MD, shares opinion on the role of checkpoint inhibitors for GI malignancies

video-image

Philip Philip, MD, on the phase 2 study comparing chemo with or without veliparib in pancreas

video-image

Philip Philip, MD, shares opinion on treatment of a BRCA+ pancreatic cancer patient

video-image

Philip Philip, MD, explains how physicians should test for BRCA in pancreatic cancer patients

video-image

Philip Philip, MD, on the outcomes of the POLO study and its importance to physicians

video-image

Daneng Li, MD, regarding the role of immunotherapy in the neoadjuvant and adjuvant setting for HCC

video-image

Daneng Li, MD, shares latest thoughts on checkpoint inhibitors being combines with TKIs

video-image

Richard Kim, MD, on the combination of cabozantinib and checkpoint inhibitors to improve HCC outcomes

video-image

Philip Philip, MD, provides thoughts on the role of PARP inhibitors in advanced pancreatic cancer

video-image

David H Ilson, MD, shares results of the ARTDECO study and it's importance to physicians

video-image

Zev Wainberg, MD, shares results of study regarding gastric and GE cancers presented at ASCO GI

video-image

Richard Kim, MD, on the outcome on the IMBRAVE 150 study & the possibility of new treatment standard

video-image

Daneng Li, MD, on combining cabozantinib with checkpoint inhibitors to improve patient outcomes

video-image

Richard Kim, MD determines whether checkpoint inhibitors combine with regorafenib for HCC treatment

video-image

Daneng Li, MD, on impressions of patient reported outcomes from the IMBRAVE 150 study

video-image

Hani Babiker, MD, elaborates on tumor treatment fields applying to GI malignancies

video-image

Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields

video-image

Ahmed Kaseb, MD, on combining cabozantinib with checkpoint inhibitors for treatment of HCC

video-image

Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study

video-image

Nevena Damjanov, MD, on impressions of the study combining cabozantinib with checkpoint inhibitors in advanced HCC patients

video-image

Nevena Damjanov, MD, elaborates on the role of TKIs in managing 2nd line HCC patients

video-image

Nevena Damjanov, MD, explains the outcomes of combining atezolizumab with bevacizumab in 1st line HCC patients

video-image

Eileen O'Reilly, MD, on the phase 2 study comparing chemo with or without veliparib in pancreas

video-image

Eileen O'Reilly, MD, provides evidence to inform treatment of pancreatic cancer patients

video-image

Manish Shah, MD, regarding the use of liquid biopsy to diagnose and treat GI cancers

video-image

Manish Shah, MD, on the role of Cyramza in the treatment of gastric and esophageal cancers

video-image

Daniel Catenacci, MD, discusses margetuximab in the treatment of esophageal and gastric cancer

video-image

Daniel Catenacci, MD, elaborates on the outcomes of the JAVELIN 100 study presented at ASCO GI 2020

video-image

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

video-image

David Ilson, MD, PhD, on the use of biomarkers in the treatment of esophagogastric cancer

video-image

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

video-image

David Ilson, MD, PhD, summarizes the role of I-O in esophagogastric cancer treatment algorithms

video-image

John Strickler, MD, shares thoughts on molecular subtyping of pancreatic cancer

video-image

John Strickler, MD, regarding pembrolizumab vs. chemotherapy in 2nd line advanced esophageal cancer

video-image

John Strickler, MD, on combo pembrolizumab, trastuzumab, capecitabine & oxaliplatin in mEGA

video-image

Raymond Wadlow, MD, on surrogate biomarkers in the treatment of hepatocellular carcinoma

video-image

Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC

video-image

Zev Wainberg, MD, regarding the results of the ROAR basket trial from GI 2019

video-image

Raymond Wadlow, MD, speculates on the use of TKIs in the management of HCC

video-image

Zev Wainberg, MD, considers regorafenib in locally advanced biliary tract cancer

video-image

David Ilson, MD, PhD, on pembrolizumab, trastuzumab, capecitabine & oxaliplatin in HER2+ mEGA

video-image

Zev Wainberg, MD, on checkpoint inhibition with chemotherapy in pancreatic cancer

video-image

Raymond Wadlow, MD, on the outcomes of Keynote 181 in esophageal cancer

video-image

Bassel El-Reyes, MD, speculates on promising novel therapies being developed for pancreatic cancer

video-image

Bassel El-Reyes, MD, considers upfront surgery for resectable pancreatic cancer

video-image

Martine Extermann, MD, PhD, on identifying the right treatment for patients with gastric cancer

video-image

Bassel El-Reyes, MD, offers his opinion on NGS & BRCA gene testing for pancreatic cancer

video-image

Martine Extermann, MD, PhD, shares the results of the FOLFOX +/- andecaliximab study from GI '19

video-image

Bassel El-Reyes, MD, regarding molecular subtyping of pancreatic cancer

video-image

Martine Extermann, MD, PhD, on the investigation of TAS-102 in metastatic gastric cancer

video-image

Bassel El-Reyes, MD, on screening patients at high risk for pancreatic cancer

video-image

Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer

video-image

David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer

video-image

Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC

video-image

David Ilson, MD, PhD, shares results from the TAGS trial presented at GI 2019

video-image

Rachna Shroff, MD, gives her take on pre-operative therapy in resectable pancreatic cancer

video-image

Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma

video-image

Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma

video-image

Rachna Shroff, MD, discusses how BRAF mutations figure into cholangiocarcinoma treatment

video-image

Rachna Shroff, MD, expands on targeted therapies in the treatment of cholangiocarcinoma

video-image

Richard Kim, MD, on the role of BRAF mutations in treatment of cholangiocarcinoma

video-image

Richard Kim, MD, regarding targeted therapies in treatment of cholangiocarcinoma

video-image

Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC

video-image

Andrew X. Zhu, MD, PhD, on what physicians should know about sequencing TKIs in HCC

video-image

Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC

video-image

Alan Venook, MD, shares key takeaways from GI 2019 regarding the treatment of biliary tract cancers

video-image

Alan Venook, MD, on the latest in identifying valid biomarkers in the treatment of HCC

video-image

Philip Philip MD, PhD, FRCP, on promising novel therapies for pancreatic cancer

video-image

Nevena Damjanov, MD, regarding the impact of the ReDOS study in HCC

video-image

Philip Philip MD, PhD, FRCP, provides opinion on NGS and BRCA gene testing in pancreatic cancer

video-image

Nevena Damjanov, MD, elaborates on stereotactic body radiation therapy in early stage HCC

video-image

Philip Philip MD, PhD, FRCP, considers molecular subtyping of pancreatic cancer

video-image

Nevena Damjanov, MD, regarding sequencing TKIs in hepatocellular carcinoma (HCC)

video-image

Philip Philip MD, PhD, FRCP, on screening patients at high risk for pancreatic cancer

video-image

Nevena Damjanov, MD, shares thoughts on the role of systemic therapy in HCC

video-image

Michael Soulen, MD, discusses the most compelling presentations from ASCO GI 2018

video-image

Michael Soulen, MD, compares the possible benefits of retrospective vs. prospective trials

video-image

Michael Soulen, MD, on the practice changing potential of data presented at his ASCO GI tumor board

video-image

Michael Soulen, MD, tells us about significant data coming out of the tumor board at ASCO GI 2018

video-image

Philip Philip, MD, PhD, FRCP, on the implications of the LAPACT study presented at ASCO 2018

video-image

Philip Philip, MD, PhD, FRCP, considers the impact of immunotherapy agents in pancreatic cancer

video-image

Philip Philip, MD, PhD, FRCP, regarding key unmet needs in pancreatic ductal adenocarcinoma

video-image

Nevena Damjanov, MD, shares the latest news in systemic therapy for advanced HCC at ASCO 2018

video-image

Nevena Damjanov, MD, on the use of pembrolizumab in HCC patients previously treated with sorafenib

video-image

Nevena Damjanov, MD, outlines the role of TACE with systemic therapy in HCC patients

video-image

David Ilson, MD, PhD, considers how to assess response in gastroesophageal cancer patients

video-image

Nevena Damjanov, MD, discusses current treatment options and sequencing TKIs in HCC

video-image

Nevena Damjanov, MD, considers the shortcomings of RECIST in measuring efficacy in HCC patients

video-image

Richard Kim, MD, offers analysis of the RAINFALL study in metastatic gastric & GE junction cancer

video-image

Richard Kim, MD, discusses pembrolizumab as an effective agent in HCC management

video-image

Richard Kim, MD, considers the effectiveness of combination sorafenib and TACE in HCC patients

video-image

Richard Kim, MD, on the use and sequencing of TKIs in hepatocellular carcinoma (HCC)

video-image

David Ilson, MD, PhD, discusses what can be done to improve outcomes in esophageal adenocarcinoma

video-image

David Ilson, MD, PhD, examines the results of the RAINFALL study at ASCO GI 2018

video-image

David Ilson, MD, PhD, on strategies for managing gastroesophageal patients after neoadjuvant therapy

video-image

David Ilson, MD, PhD, on how we can individualize treatment of gastroesophageal cancer patients

video-image

Andrew Zhu, MD, PhD, on the effectiveness of pembrolizumab in HCC patients treated with sorafenib

video-image

Andrew Zhu, MD, PhD, shares thoughts on treating adjuvant hepatocellular carcinoma (HCC) today

video-image

Laura Dawson, MD, FRCPC, on additional randomized studies of external beam radiation

video-image

Laura Dawson, MD, FRCPC, tells us about the results of the START study

video-image

Laura Dawson, MD, FRCPC, discusses the design of the START study in HCC

video-image

Laura Dawson, MD, FRCPC, provides some background on hepatocellular carcinoma (HCC)

video-image

Alan Venook, MD, outlines the role of liquid biopsy in gastrointestinal cancers

video-image

Khaldoun Almhanna, MD, MPH, offers opinion on the best way to manage early gastric cancer

video-image

Khaldoun Almhanna, MD, MPH, discusses the risk factors to watch for gastroesophageal cancer

video-image

Kenneth Wang, MD, offers opinion on approaches to treating esophageal cancer

video-image

Kenneth Wang, MD, on managing esophageal cancer patients who have completed neoadjuvant therapy

video-image

Kenneth Wang, MD, on how to assess response in esophageal cancer and utilize the information

video-image

Andrew Zhu, MD, PhD, shares the latest in systemic therapy for advanced HCC at ASCO GI 2018

video-image

Andrew Zhu, MD, PhD, on how we diagnose and assess response in HCC patients

video-image

Khaldoun Almhanna, MD, MPH, on surveillance and the management of gastroesophageal cancer

video-image

Kenneth Wang, MD, considers how staging esophageal cancer has changed and improved

video-image

Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study

video-image

Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study

video-image

John L. Marshall, MD, talks about the results of the RESORCE trial

video-image

John L. Marshall, MD, on how checkpoint inhibitors are being integrated into treatment of GI cancers

video-image

John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies

video-image

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

video-image

Philip Philip, MD, on whether resected pancreatic cancer patients should be offered adjuvant therapy

video-image

Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy

video-image

Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib

video-image

Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients

video-image

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

video-image

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

video-image

Thomas A. Abrams, MD, on whether physicians will incorporate regorafenib into clinical practice

video-image

Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment

video-image

Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients

video-image

Howard S. Hochster, MD, differentiates regorafenib from 5FU and TAS-102

video-image

Ghassan Abou-Alfa, MD, discusses how checkpoint inhibitors be incorporated into the treatment

video-image

Ghassan Abou-Alfa, MD, on identifying subgroups of patients for targeted therapies in HCC

video-image

Ghassan Abou-Alfa, MD, discusses if regorafenib will be incorporated into clinical practice

video-image

Ghassan Abou-Alfa, MD, discusses the outcomes of the RESORCE trial

video-image

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

video-image

Nevena Damjanov, MD, explains how checkpoint inhibitors will be incorporated into the treatment

video-image

Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, on whether regorafenib will be integrated into clinical practice

video-image

Nevena Damjanov, MD, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Nevena Damjanov, MD, discusses how new agents for advanced HCC will be integrated into the treatment

video-image

Johanna Bendell, MD, talks about the Proprietary Neoantigen Identification Technology platform

video-image

Johanna Bendell, MD, discusses the RESORCE trial data

video-image

Johanna Bendell, MD, discusses some of the challenges in treating pancreatic cancer

video-image

Johanna Bendell, MD, on some of the exciting trials or drugs in development in pancreatic cancer

video-image

Johanna Bendell, MD, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017

video-image

Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Jeffrey A. Meyerhardt, MD, discusses how consensus molecular subtypes help with CRC treatment

video-image

Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach

video-image

Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer

video-image

Edith P. Mitchell, MD, discusses the goals of the NCI-MATCH trial and the progress to date

video-image

Edith P. Mitchell, MD, on how the Blue Ribbon Panel may help with the Cancer Moonshot initiative

video-image

Edith P. Mitchell, MD, discusses integrating immunotherapy into treatment regimens for CRC patients

video-image

Edith P. Mitchell, MD, explains how organoids are being used for cancer biology research

video-image

TAS-102 versus 5-flourouracil and other more familiar agents ASCO GI 2016

video-image

RECOURSE trial did performance status impact benefit from TAS-102 at ASCO GI 2016

video-image

Design of the RECOURSE trial on which the FDA approved TAS-102

video-image

Potential cases to use Regorafenib over TAS-102 ASCO GI 2016

video-image

More money should be allocated to early detection and screening in colorectal cancer ASCO GI 2016

video-image

PD-L1 markers in MMR deficient cancers ASCO GI 2016

video-image

Mismatch Repair (MMR) deficient and the use of PD-1 blockade ASCO GI 2016

video-image

Planned studies to evaluate immune checkpoint inhibitors in MMR deficient GI cancers ASCO Gi 2016

video-image

Does the Asian population differ from the western populations in regards to gastric cancers

video-image

The future of gastric cancers will be targeted agents including immunotherapy

video-image

FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma

video-image

Phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma

video-image

Managing patients on regorafenib including adverse events

video-image

Next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies

video-image

KEYNOTE-028 results with pembrolizumab

video-image

Pembrolizumab looks promising according to KEYNOTE-028 results

video-image

Pancreatic Cancer News from ASCO GI 2016

video-image

Weekly T-DM1 surprising or disappointing ASCO GI 2016

video-image

GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016

video-image

Using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas ASCO GI 2016

video-image

Post-operative adjuvant therapy for resectable patients with node positive oesophageal cancer ASCO GI 2016

video-image

FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016

video-image

TAS-102 and how it differ from more familiar agents, such as 5-flourouracil, capecitabine and S-1

video-image

RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib

video-image

Importance of performance status prior to starting regorafenib at ASCO GI 2016